New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 23, 2019 - AbbVie announced the FDA approval of Skyrizi (risankizumab-rzaa), for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Download PDF
Return to publications
